WallStSmart

Akso Health Group ADR (AHG)vsCardinal Health Inc (CAH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 1655579% more annual revenue ($244.67B vs $14.78M). CAH leads profitability with a 68.0% profit margin vs 0.0%. CAH earns a higher WallStSmart Score of 53/100 (C-).

AHG

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

CAH

Buy

53

out of 100

Grade: C-

Growth: 7.3Profit: 7.5Value: 8.7Quality: 5.8
Piotroski: 4/9Altman Z: 4.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AHG.

CAHUndervalued (+13.6%)

Margin of Safety

+13.6%

Fair Value

$259.58

Current Price

$207.83

$51.75 discount

UndervaluedFair: $259.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
415.8%10/10

Revenue surging 415.8% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

CAH4 strengths · Avg: 9.5/10
Profit MarginProfitability
68.0%10/10

Keeps 68 of every $100 in revenue as profit

Operating MarginProfitability
123.0%10/10

Strong operational efficiency at 123.0%

Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
18.8%8/10

18.8% revenue growth

Areas to Watch

AHG4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$807.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

CAH2 concerns · Avg: 3.5/10
P/E RatioValuation
30.3x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 415.8% demonstrates continued momentum.

Bull Case : CAH

The strongest argument for CAH centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 68.0% and operating margin at 123.0%. Revenue growth of 18.8% demonstrates continued momentum.

Bear Case : AHG

The primary concerns for AHG are EPS Growth, Market Cap, Profit Margin.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity.

Key Dynamics to Monitor

AHG profiles as a hypergrowth stock while CAH is a growth play — different risk/reward profiles.

CAH carries more volatility with a beta of 0.62 — expect wider price swings.

AHG is growing revenue faster at 415.8% — sustainability is the question.

CAH generates stronger free cash flow (555M), providing more financial flexibility.

Bottom Line

CAH scores higher overall (53/100 vs 24/100), backed by strong 68.0% margins and 18.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and integrated patient care services. With a specialization in advanced health technologies, the company is well-positioned to tap into growth opportunities in telehealth and personalized medicine, bolstered by a strong commitment to research and development. Its robust business model and dedication to quality, supported by a skilled team of professionals, make Akso Health Group an appealing investment for institutional investors aiming to navigate the transformative landscape of healthcare.

Visit Website →

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Want to dig deeper into these stocks?